Skip to main content

Jubilant Life, Cipla rally up to 6% on inking pact with Gilead Sciences

According to the statements issued by Jubilant Life and Cipla, both the firms will have the right to register, manufacture and sell Gilead's Remdesivir drug in 127 countries including India

from Home Page https://ift.tt/2WS6TXv

Comments

Popular posts from this blog